NCT00372892View on ClinicalTrials.gov

Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

June 30, 2011

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

Rituximab

375mg/m2 per week for 4 consecutive weeks

DRUG

Placebo

Saline IV placebo once per week for 4 consecutive weeks

Trial Locations (7)

V6Z 2A5

St. Paul's Hospital, Vancouver

B3H 1V7

Queen Elizabeth II Health Sciences Centre, Halifax

L8N3Z5

McMaster Univerisity, Hamilton

N2G 1G3

Grand River Regional Cancer Centre, Kitchener

N6A 4S2

London Health Sciences Centre, London

K1H 8L6

Ottawa Health Research Institute, Ottawa

M5G 2C4

University Health Network, Toronto

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Hamilton Health Sciences Corporation

OTHER

NCT00372892 - Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) | Biotech Hunter | Biotech Hunter